The Pharma Letter15h
FDA lifts clinical hold on Entrada’s ENTR-601-44 study
The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ...
BioPharma Dive16h
Regeneron gene therapy helps deaf children hear in small study
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
The Pharma Letter17h
Regeneron’s DB-OTO demonstrates dramatic hearing improvement
US biotech Regeneron Pharmaceuticals says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing ...
Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...
pharmaphorum19h
Evidence builds behind Regeneron's deafness gene therapy
Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...